All In Biotech

Drug Trial Radar · NCT02157376

Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients

Effect of Intravenous Esomeprazole Versus Cimetidine in Prevention of Stress Ulcer Prophylaxis in Chinese Seriously Ill Patients - a Randomized, Double-blind, Parallel-group Study

Last checked: Nov 21, 2026Latest source record: Mar 10, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 343 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

343

Actual

Start

Jul 2014

Primary completion

Feb 2016

Study completion Feb 2016

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 6, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The efficacy of esomeprazole will be compared versus cimetidine (a drug that previously demonstrated prevention of bleeding events) during treatment period in proportion of patients for the prevention of upper GI bleeding.

Conditions

  • Stress Ulcer Prophylaxis

Interventions

  • EsomeprazoleDrug

    iv esomeprazole 30 min intermittent infusions given for maximum 14 days

  • CimetidineDrug

    iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation PhaseTime frame: 1-14 days

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Baotou, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Chongqing, China

  • Research Site

    Fuzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guilin, China

  • Research Site

    Haikou, China

  • Research Site

    Qingdao, China

  • Research Site

    Shanghai, China

  • Research Site

    Shenzhen, China

  • Research Site

    Tianjin, China

  • Research Site

    Ürümqi, China

  • Research Site

    Xi'an, China

  • Research Site

    Zhanjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.